Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). 


The Company has generated clinical proof of concept data in two important itch conditions: uremic pruritus and prurigo nodularis.

Trevi Therapeutics Names Michael Heffernan to its Board of Directors
Senior pharma executive brings clinical development and commercial background as the Company moves into Phase 3 trials for Nalbuphine ER in chronic pruritus conditions
Trevi Therapeutics Selected to Present at the American Society of Nephrology's Kidney Week 2016 Phase 2/3 Data for NalbuphineER in Uremic Pruritus
Presentation Abstract: Time Course of Reduction in Itch Intensity During and Following Treatment with Nalbuphine ER Tablets: A Randomized, Placebo-Controlled Trial in Patients with Uremic Pruritus
Trevi Therapeutics Announces Positive Results from Phase 2 Trial in Prurigo Nodularis
Oral Nalbuphine ER trial achieved positive results of reduced itch intensity and other supporting efficacy endpoints in prurigo nodularis patients